Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > KOL Webinar Advert for Nov 14
View:
Post by westcoast1000 on Oct 25, 2022 11:07am

KOL Webinar Advert for Nov 14

KOL Webinar on Pancreatic Cancer and Interim Results from the Phase 1/2 GOBLET Study Being Presented at the SITC 37th Annual Meeting

 

Monday, November 14, 2022 | 10:00 AM ET

 

Hosted by Oncolytics Biotech Inc 

(NASDAQ: ONCY, TSX: ONC)

Join us for a virtual key opinion leader (KOL) event with Oncolytics Biotech, featuring Dirk Arnold, MD, PhD (Asklepios Tumorzentrum Hamburg), Andrea Bullock, MD, MPH (Beth Israel Deaconess Medical Center) and Thomas Seufferlein, MD, PhD (Ulm University, Germany).

 

During the event, the KOLs and members of the Oncolytics management team will discuss the current treatment landscape and unmet medical need in pancreatic cancer, as well as interim results from the Phase 1/2 GOBLET study’s pancreatic cancer cohort being presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

 

A live question and answer session will follow the formal presentations.

____

The bios of the three featured speakers are included. They are impressive and very well connected.

I got this advert through email this morning.

All the best to the longs.

Comment by Snowdrift on Oct 25, 2022 11:37am
Here's how to register for the event : https://lifesci.rampard.com/WebcastingAppv5/Events/eventsDispatcher.jsp?Y2lk=MjA1Mg==
Comment by canasol46 on Oct 25, 2022 12:23pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities